Publications by authors named "Bob Goodenow"

Claim this Profile
H
HBI-8000, HUYABIO Lead Clinical Program, Is a Selective Histone Deacetylase Inhibitor With Therapeutic Benefits in Leukemia and in Solid Tumors.
Farbod Shojaei, Bob Goodenow, Gloria Lee, Fairooz Kabbinavar, Mireille Gillings

Front Oncol· January 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The epigenetic immunomodulator, HBI-8000, enhances the response and reverses resistance to checkpoint inhibitors.
Reid P Bissonnette, Rosemary M Cesario, Bob Goodenow, Farbod Shojaei, Mireille Gillings

BMC Cancer· August 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis